Asceneuron is a clinical stage biotech company that is dedicated to developing orally bioavailable therapeutics for neurodegenerative disorders with a high unmet medical need. With a focus on debilitating conditions such as Alzheimer's and Parkinson's disease, Asceneuron aims to discover and develop small molecule therapeutics that treat the root cause of neurodegeneration. Their goal is to significantly improve the quality of life for patients suffering from neurodegenerative diseases.

Founded in 2012, Asceneuron emerged as a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio and research group in Switzerland. The company is privately held and backed by a strong syndicate of investors including Sofinnova Partners, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Kurma Partners, and Merck Ventures.

With a team of experienced drug developers and scientists, Asceneuron operates to the highest standards of scientific excellence and a patient-focused approach. Their research and development efforts are supported by prestigious grants and research awards from renowned foundations like Cure PSP, the Alzheimer’s Drug Discovery Foundation, and The Michael J Fox Foundation. Asceneuron is currently focused on the clinical development of two small molecule O-GlcNAcase inhibitors (ASN51 and ASN90) as potential treatments for proteinopathies characterized by the accumulation of toxic protein aggregates within cells.

Through their innovative approach and dedication, Asceneuron aims to transform the lives of patients suffering from neurodegenerative proteinopathies